LDB

Enterome's OncoMimics™ peptide-based immunotherapy EO2401 generates and maintains elevated anti-tumor T cell responses for more than 10 months in patients with recurrent glioblastoma

Retrieved on: 
Thursday, November 10, 2022

PARIS, Nov. 10, 2022 /PRNewswire/ -- Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces updated safety, immunogenicity and efficacy data of its Phase 1/2 clinical trial of EO2401 in combination with an immune checkpoint inhibitor (nivolumab) +/- an anti-VEGF therapy (bevacizumab), for the treatment of patients with first progression/recurrence of glioblastoma (ROSALIE trial). The data were presented in an oral and a poster presentation at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Boston, MA, US, today.

Key Points: 
  • EO2401 includes synthetically produced HLA-A2 peptides with molecular mimicry to TAAs upregulated in glioblastoma (IL13Ra2, BIRC5 and FOXM1) and the CD4 helper peptide UCP2.
  • EO2401 in combination with nivolumab generated strong systemic immune responses through activation of specific effector memory CD8+ T cells, correlating with clinical efficacy.
  • Additional patients are to be treated with triple combination of EO2401 in combination with nivolumab and bevacizumab to support final regimen selection.
  • The trial is assessing safety, tolerability, immunogenicity and preliminary efficacy in approximately 80 patients at centers in the US and Europe.

Enterome's OncoMimics™ peptide-based immunotherapy EO2401 generates and maintains elevated anti-tumor T cell responses for more than 10 months in patients with recurrent glioblastoma

Retrieved on: 
Thursday, November 10, 2022

PARIS, Nov. 10, 2022 /PRNewswire/ -- Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces updated safety, immunogenicity and efficacy data of its Phase 1/2 clinical trial of EO2401 in combination with an immune checkpoint inhibitor (nivolumab) +/- an anti-VEGF therapy (bevacizumab), for the treatment of patients with first progression/recurrence of glioblastoma (ROSALIE trial). The data were presented in an oral and a poster presentation at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Boston, MA, US, today.

Key Points: 
  • EO2401 includes synthetically produced HLA-A2 peptides with molecular mimicry to TAAs upregulated in glioblastoma (IL13Ra2, BIRC5 and FOXM1) and the CD4 helper peptide UCP2.
  • EO2401 in combination with nivolumab generated strong systemic immune responses through activation of specific effector memory CD8+ T cells, correlating with clinical efficacy.
  • Additional patients are to be treated with triple combination of EO2401 in combination with nivolumab and bevacizumab to support final regimen selection.
  • The trial is assessing safety, tolerability, immunogenicity and preliminary efficacy in approximately 80 patients at centers in the US and Europe.

B.C.’S HOSPITALITY AND TOURISM BUSINESSES URGE SWIFT END TO BCGEU JOB ACTION

Retrieved on: 
Wednesday, August 24, 2022

General Employees Union (BCGEU), urging a swift resolution when the two parties return to the bargaining table.

Key Points: 
  • General Employees Union (BCGEU), urging a swift resolution when the two parties return to the bargaining table.
  • On Aug. 15, the BCGEU commenced job action outside four key Liquor Distribution Branch warehouses, which together supply about 40 per cent of all alcohol in B.C.
  • Though intended to motivate the provincial government, the BCGEUs job action strikes yet another crushing blow to the hospitality and tourism sector, which is only beginning to recover after the devastating impacts of the COVID-19 pandemic.
  • This labour dispute has nothing to do with our sector; were collateral damage in this job action, said Jeff Guignard, executive director of the Alliance of Beverage Licensees (ABLE BC).

Bay Area Lyme Foundation Selects National Winners of the 2022 Emerging Leader Awards Aimed at Making Lyme Disease Easy to Diagnose and Simple to Cure

Retrieved on: 
Tuesday, August 9, 2022

Both of the award winners will utilize biological samples from the Lyme Disease Biobank , a program of Bay Area Lyme Foundation lead by principal investigator Liz Horn, PhD, MBI, to collect well-characterized human tissue, blood, and urine specimens to accelerate research for Lyme disease and other tick-borne infections.

Key Points: 
  • Both of the award winners will utilize biological samples from the Lyme Disease Biobank , a program of Bay Area Lyme Foundation lead by principal investigator Liz Horn, PhD, MBI, to collect well-characterized human tissue, blood, and urine specimens to accelerate research for Lyme disease and other tick-borne infections.
  • Developing sensitive and specific diagnostics for acute and persistent Lyme disease should be the highest priority in Lyme disease research.
  • Bay Area Lyme Foundation , a national organization committed to making Lyme disease easy to diagnose and simple to cure, is the leading public not-for-profit sponsor of innovative Lyme disease research in the US.A 501c3 charity based in Silicon Valley, Bay Area Lyme Foundation collaborates with world-class scientists and institutions to accelerate medical breakthroughs for Lyme disease.
  • The Lyme Disease Biobank (LDB), a program of the Bay Area Lyme Foundation, is working to accelerate research of Lyme disease and other tick-borne infections.

Bay Area Lyme Foundation Funds $8M in Tick-borne Disease Research During the Pandemic

Retrieved on: 
Tuesday, January 25, 2022

The Lyme Disease Biobank (LDB) , a program of the Bay Area Lyme Foundation, was created because medical researchers were unable to access the human blood, urine, and tissue samples they needed for their research.

Key Points: 
  • The Lyme Disease Biobank (LDB) , a program of the Bay Area Lyme Foundation, was created because medical researchers were unable to access the human blood, urine, and tissue samples they needed for their research.
  • LDB collects samples from people with early Lyme, as well as people with chronic/persistent Lyme.
  • As a result of the difficulty in diagnosing and treating Lyme disease, more than one million Americans may be suffering from the impact of its debilitating long-term symptoms and complications, according to Bay Area Lyme Foundation estimates.
  • Bay Area Lyme Foundation , a national organization committed to making Lyme disease easy to diagnose and simple to cure, is the leading public not-for-profit sponsor of innovative Lyme disease research in the US.A 501c3 charity based in Silicon Valley, Bay Area Lyme Foundation collaborates with world-class scientists and institutions to accelerate medical breakthroughs for Lyme disease.

DASH Regulatory Technologies Launches New Security-Based Swaps (SBS) Solution

Retrieved on: 
Tuesday, November 9, 2021

New York, Nov. 09, 2021 (GLOBE NEWSWIRE) -- DASH Regulatory Technologies (DRT) the regtech-focused affiliate of U.S. options technology and execution services provider DASH Financial Technologies today announced the launch of a new Security-Based Swaps (SBS) add-on to its industry-leading DASH 360R regulatory reporting solution.

Key Points: 
  • New York, Nov. 09, 2021 (GLOBE NEWSWIRE) -- DASH Regulatory Technologies (DRT) the regtech-focused affiliate of U.S. options technology and execution services provider DASH Financial Technologies today announced the launch of a new Security-Based Swaps (SBS) add-on to its industry-leading DASH 360R regulatory reporting solution.
  • In addition, DASH Regulatory Technologies actively collaborated with clients during the development process to solidify its understanding of the finalized SBS ruleset.
  • Commenting on the launch of the new SBS solution, Venu Palaparthi, DASH Regulatory Technologies Managing Director, said: With the passage of the Dodd-Frank legislation, security-based swaps became treated as securities.
  • Founded in 1987 as LDB Consulting, DASH Regulatory Technologies is DASHs regtech-focused affiliate.

Proactive news headlines including Entain, Loncor, NexTech AR, Western Magnesium and ME2C Environmental

Retrieved on: 
Tuesday, September 21, 2021

Proactives network reaches over 12 million engaged private, professional and institutional investors looking for opportunities.

Key Points: 
  • Proactives network reaches over 12 million engaged private, professional and institutional investors looking for opportunities.
  • Our written and video content is published on Proactive sites that collectively attract up to 10 million views per month.
  • We help the world understand what makes companies stand out from the crowd with in-depth investment research from a team of experienced analysts.
  • For more information on how Proactive can help you make a difference, email us at [email protected]

Pure Extracts Ships Initial Vape Cart Order to BC Liquor Distribution Branch

Retrieved on: 
Thursday, August 12, 2021

VANCOUVER, British Columbia, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (Pure Extracts or the Company), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging psychedelic sector, is pleased to announce that its wholly owned subsidiary, Pure Extracts Manufacturing Corp., has shipped its initial order of one-gram, full spectrum oil (FSO) vape carts via its distribution partner to the British Columbia Liquor Distribution Branch (LDB).

Key Points: 
  • VANCOUVER, British Columbia, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (Pure Extracts or the Company), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging psychedelic sector, is pleased to announce that its wholly owned subsidiary, Pure Extracts Manufacturing Corp., has shipped its initial order of one-gram, full spectrum oil (FSO) vape carts via its distribution partner to the British Columbia Liquor Distribution Branch (LDB).
  • As consumer preferences mature, demand for Pure Extracts Pure Pulls branded vape carts is high within the provincial markets as this product also offers exceptional value to the consumer while generating high margins for the Company.
  • The combination of a larger form factor with our exceptional cannabis extracts will build on the loyal following Pure Pulls already has in place and continue to make the vape cart business a material revenue producer for Pure Extracts.
  • Pure Extracts Technology Corp. features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia.

Pure Extracts Ships Initial Edible Cannabis Gummies Order to British Columbia

Retrieved on: 
Thursday, August 5, 2021

VANCOUVER, British Columbia, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (Pure Extracts or the Company), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging psychedelic sector, is pleased to announce that its wholly owned subsidiary, Pure Extracts Manufacturing Corp., has shipped its initial order of edible cannabis gummies via its distribution partner to the British Columbia Liquor Distribution Branch (LDB).

Key Points: 
  • VANCOUVER, British Columbia, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (Pure Extracts or the Company), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging psychedelic sector, is pleased to announce that its wholly owned subsidiary, Pure Extracts Manufacturing Corp., has shipped its initial order of edible cannabis gummies via its distribution partner to the British Columbia Liquor Distribution Branch (LDB).
  • We are excited to have shipped our first order for Fire Burst cinnamon flavoured Pure Chews to the LDB, the wholesaler serving our home province of British Columbia, said Ben Nikolaevsky, CEO.
  • The edible gummie business is a material revenue producer for Pure Extracts.
  • at https://www.bccannabisstores.com/
    Pure Extracts Technology Corp. features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia.

Pure Extracts Receives Purchase Order from British Columbia

Retrieved on: 
Thursday, May 27, 2021

VANCOUVER, British Columbia, May 27, 2021 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (Pure Extracts or the Company), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging psychedelic sector, is pleased to announce that its wholly owned subsidiary, Pure Extracts Manufacturing Corp., through its distribution partner, has received an initial purchase order (PO) for its edible cannabis gummies from the British Columbia Liquor Distribution Branch (LDB).

Key Points: 
  • VANCOUVER, British Columbia, May 27, 2021 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (Pure Extracts or the Company), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging psychedelic sector, is pleased to announce that its wholly owned subsidiary, Pure Extracts Manufacturing Corp., through its distribution partner, has received an initial purchase order (PO) for its edible cannabis gummies from the British Columbia Liquor Distribution Branch (LDB).
  • The edible gummie business is a material revenue producer for Pure Extracts, said Ben Nikolaevsky, CEO.
  • Pure Extracts Technology Corp. features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia.
  • Health Canada, under the Cannabis Act, granted Pure Extracts its Standard Processing License on September 25, 2020.